Abilify - Biotech, Pharma and Life Science Channel
Abilify (Aripiprazole) is an atypical antipsychotic produced by Bristol-Myers Squibb Company, with annual sales of $3m, ranking it 6th in the world for annual sales.
Abilify is prescribed in addition to other anti-depressants for the treatment of depression, and additionally for bipolar disorder and schizophrenia. The FDA has recently licensed it for use in treating irritability associated with Autistic Disorder in pediatric patients (ages 6 to 17), as part of a total treatment plan.
Source; Adapted from Bioportfolio.com and Abilify.com
Add the Abilify News Channel to your RSS reader;
Follow the Abilify Twitter feed;
News Articles
Preliminary study analysis assessed total psychiatric hospitalization rates for patients with schizophrenia previously taking oral antipsychotics who were converted t...
Drugs.com Releases Q1 Sales for Top 100 U.S. Drugs: Rough U.S Flu Season Boosts Numbers for Tamiflu
NEW YORK, May 6, 2013 /PRNewswire/ -- Drugs.com, the leading online clinical drug resource, today released first quarter 2013 U.S. prescription sales data for the top 100 drugs. (Photo: http://...
H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced a license and development agreement for Lu AE58054, a selective 5HT6 receptor antagonist cu...
Otsuka Pharmaceutical Co., Ltd. (Otsuka) and H. Lundbeck A/S (Lundbeck) today outlined co-promotion plans and summarized the overall progress in their global alliance at a session...
Otsuka Pharmaceutical Co., Ltd. (Otsuka) and H. Lundbeck A/S (Lundbeck) announced the U.S. Food and Drug Administration (FDA) has approved ABILIFY MAINTENA™ (aripiprazole) for e...
Alkermes plc (NASDAQ: ALKS) today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application 12/823,0...
Pending EC decision: Abilify, aripiprazole, Opinion date: 13-Dec-2012
NEW YORK, Nov. 21, 2012 /PRNewswire/ -- As in the previous quarter, proton-pump inhibitors, antipsychotics and statins remain in the top-selling therapeutic categories. Merck's asthma and allergy...
Most Read Pharmaceutical and Health Condition News - August '12
AUSTIN, Texas, Sept. 14, 2012 /PRNewswire/ -- dailyRx, Inc., a leading digital publisher, announced today the top five health conditions and medications viewed on the dailyRx News Network™...
Events
None
Companies
None
Clinical Trials
Anticonvulsant Mood Stabilizers, Antipsychotic Drugs and the Insulin Resistance Syndrome
The objective of this study is to determine the effect of various mood stabilizers (MS) on the insulin resistance syndrome (IRS; also called the metabolic syndrome) alone and in patients...
An Open-Label Trial of Aripiprazole in Children and Adolescents With Bipolar Disorder
This is an investigator-initiated study whose primary aim is to determine the effectiveness of aripiprazole (Abilify®) in helping persons with symptoms of mania whose current medications...
Cognitive Improvement With Aripiprazole (Abilify) in Patients With Schizophrenia (BMS)
Evaluation of cognitive ability in patients with schizophrenia or schizoaffective disorder both before and after a switch from risperidone to aripiprazole may reveal some of the cognitive...
Abilify Therapy for Reducing Comorbid Substance Abuse
It is hypothesized that the use of aripiprazole (Abilify) in patients with alcohol and/or drug dependence with comorbid psychiatric conditions will lead to: - Reduction in the amount o...
Aripiprazole in Late Life Bipolar Disorder
The purpose of this research study is to analyze the effectiveness and tolerability of a new medication, aripiprazole (Abilify), in individuals age 50 years and older who have bipolar diso...
Study of Aripiprazole (Abilify) Versus Placebo in Children With Subsyndromal Bipolar Disorder
The purpose of this study is to test the effectiveness and tolerability/safety of aripiprazole (abilify) in children with subsyndromal symptoms of bipolar disorder who also have a bipolar...
A Combination of Two Currently Approved Drugs to Enhance the Treatment of Schizophrenia
Study of a medication for the treatment of Schizophrenia in patients who are already taking Abilify, Risperdal, Seroquel, Zyprexa
Abilify Augmentation of SSRI Therapy in Treatment Refractory Depression
Our target population will have been adequately treated with one of three SSRIs (escitalopram, citalopram, and sertraline) for at least 8-12 weeks and continue to experience symptoms of de...
Health Evaluation of Abilify Long-term Therapy
This is a post-market surveillance, and the treatment to patients will be depended upon the decision based on physician's clinical judgment. The health profiles during the switching period...
The New Strategy for Pharmacological Treatment in People With Schizophrenia
Switching from Risperidone to Aripiprazole in early stage of pharmacotherapy will demonstrate the same efficacy as compared to risperidone continuation treatment in the treatment of schiz...
PubMed Articles
None
Videos
Further Thoughts on Abilify From a Psych Grad
I present some short thoughts on Abilify (Aripiprazole). Key points: - It's dangerous! Not To be used lightly! - Ignore the television ads. - It's still usef...
